HR 9 REGULATORY RISK ASSESSMENT COMPLIANCE WOULD ADD ABOUT $20 MIL. TO FDA SPENDING ON PREMARKET ACTIVITIES, CBO ESTIMATES; HRG HAS SIMILAR PROJECTIONS
This article was originally published in The Gray Sheet
Executive Summary
FDA spending on premarket regulatory activities would increase by about $20 mil. a year if the agency is subjected to the risk assessment requirements under Title III of the "Job Creation and Wage Enhancement Act" (HR 9), the Congressional Budget Office estimates in scoring of the Commerce Committee version of the bill released Feb. 15.
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.